News
AFMD
5.28
+3.13%
0.16
Artiva: Natural Killer Cell Biotech With 1st Half Of 2025 Lupus Treatment Data
Seeking Alpha · 2d ago
Weekly Report: what happened at AFMD last week (0715-0719)?
Weekly Report · 3d ago
Artiva Biotherapeutics surges on trading debut
Artiva Biotherapeutics (ARTV) made its public trading debut on Friday. The cell therapy developer raised $167M in its initial public offering. The San Diego, California-based biotech has partnered with Affimed to develop a drug combo involving AlloNK.
Seeking Alpha · 5d ago
Weekly Report: what happened at AFMD last week (0708-0712)?
Weekly Report · 07/15 11:57
Weekly Report: what happened at AFMD last week (0701-0705)?
Weekly Report · 07/08 12:00
Weekly Report: what happened at AFMD last week (0624-0628)?
Weekly Report · 07/01 12:00
Cell therapy developer Artiva refiles for a $100M IPO
Cell therapy developer Artiva refiles for a $100M IPO. Artiva Biotherapeutics, Inc. (ARTV) is a cancer drug developer. The San Diego, California-based biotech has filed with the SEC to raise up to $100 million in an IPO.
Seeking Alpha · 06/29 14:07
Affimed Shareholders Approve Key Resolutions
TipRanks · 06/26 21:17
Weekly Report: what happened at AFMD last week (0617-0621)?
Weekly Report · 06/24 12:10
Affimed (AFMD) Gets a Buy from Truist Financial
TipRanks · 06/18 02:25
Weekly Report: what happened at AFMD last week (0610-0614)?
Weekly Report · 06/17 11:59
Analysts Offer Insights on Healthcare Companies: R1 RCM (RCM), Affimed (AFMD) and Nurix Therapeutics (NRIX)
TipRanks · 06/17 10:04
Affimed Is Maintained at Buy by Laidlaw & Co.
Dow Jones · 06/13 14:34
Affimed Price Target Raised to $25.00/Share From $15.00 by Laidlaw & Co.
Dow Jones · 06/13 14:34
Laidlaw & Co. Maintains Buy on Affimed, Raises Price Target to $25
Benzinga · 06/13 14:23
Affimed (AFMD) Receives a Buy from Truist Financial
TipRanks · 06/13 11:18
Affimed Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 06/13 10:27
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cara Therapeutics (CARA), Affimed (AFMD) and Ventyx Biosciences (VTYX)
TipRanks · 06/13 10:22
HC Wainwright & Co. Reiterates Buy on Affimed, Maintains $10 Price Target
Benzinga · 06/13 10:18
AFMD Stock Earnings: Affimed Beats EPS, Misses Revenue for Q1 2024
Affimed reported earnings per share of -$1.38 for the first quarter of 2024. The company reported revenue of $168,339. This was 87.44% worse than the analyst estimate of $1.34 million. Affimed also reported results for the fourth quarter of 2015.
Investorplace · 06/12 14:52
More
Webull provides a variety of real-time AFMD stock news. You can receive the latest news about Affimed through multiple platforms. This information may help you make smarter investment decisions.
About AFMD
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.